Evolocumab Added to Statins to Reduce Progression of Coronary Atherosclerosis

• Autores: Scott W. Murray
• Localización: JAMA: the journal of the American Medical Association, ISSN 0098-7484, Vol. 317, Nº. 16, 2017, págs. 1690-1690
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Dr Nicholls and colleagues found that adding evolocumab vs placebo to statin treatment among patients with coronary disease resulted in a 1% greater decrease in percent atheroma volume (PAV), measured by serial intravascular ultrasonography (IVUS) imaging, after 76 weeks.1 Unfortunately, IVUS examinations have inherent variability.2 Even in the best of laboratories, there are always measurement reproducibility errors but also intraoperator and interoperator variability in the actual plaque measurements.